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Abstract
Background
South Africa has one of the highest per capita rates of tuberculosis (TB) incidence in the
world. In 2012, the South African government produced a National Strategic Plan (NSP) to
control the spread of TB with the ambitious aim of zero new TB infections and deaths by
2032, and a halving of the 2012 rates by 2016.
Methods
We used a transmission model to investigate whether the NSP targets could be reached if
immediate scale up of control methods had happened in 2014. We explored the potential
impact of four intervention portfolios; 1) “NSP” represents the NSP strategy, 2) “WHO” in-
vestigates increasing antiretroviral therapy eligibility, 3) “Novel Strategies” considers new
isoniazid preventive therapy strategies and HIV “Universal Test and Treat” and 4) “Opti-
mised” contains the most effective interventions.
Findings
We find that even with this scale-up, the NSP targets are unlikely to be achieved. The portfo-
lio that achieved the greatest impact was “Optimised”, followed closely by “NSP”. The
“WHO” and “Novel Strategies” had little impact on TB incidence by 2050. Of the individual
interventions explored, the most effective were active case finding and reductions in pre-
treatment loss to follow up which would have a large impact on TB burden.
Conclusion
Use of existing control strategies has the potential to have a large impact on TB disease bur-
den in South Africa. However, our results suggest that the South African TB targets are un-
likely to be reached without new technologies. Despite this, TB incidence could be
dramatically reduced by finding and starting more TB cases on treatment.
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Introduction
South Africa suffers from an extremely high burden of tuberculosis (TB) disease: in 2013 it was
one of the top six countries ranked by number of incident TB cases (04–06 million) [1]. Glob-
ally, TB is the second leading cause of death from an infectious disease [1].
Several targets for TB control have been set by the United Nations (UN), the World Health
Organization (WHO) and the South African government for a range of indicators, with differ-
ent degrees of specificity and feasibility. For example, the UNMillennium Development Goal,
set in 2000 for 2015, to have a falling TB disease incidence globally,[2] has already been reached
[1]. However, in the Africa region, primarily because of the rise of HIV, the WHO STOP TB
goal to halve TB prevalence and deaths between 1990 and 2015,[3] is unlikely to be achieved
[1]. The South African government have produced their own National Strategic Plan (NSP) for
tackling “HIV, STIs and TB” [4]. This plan sets out ambitious aims: to halve TB incidence and
TB related mortality between 2012 and 2016, with zero new infections and zero TB mortality
by 2032.
To reach the NSP targets, the prevention strategies outlined in the plan are “based on cur-
rent knowledge” [4]. Other interventions under development, such as new TB vaccines, need
to be pursued but cannot be used to reach the 2016 target. Efforts to achieve the NSP targets
must therefore be based on existing control technologies. New combinations and optimising
existing strategies, such as providing antiretroviral therapy (ART) to all people living with HIV
(PLHIV) with TB disease and isoniazid preventive therapy (IPT) to all PLHIV pre-ART, may
be needed to fulfil the potential of existing methods.
Our aim was to use a transmission model to make a preliminary investigation as to whether
the NSP targets could be reached if immediate scale up of existing control methods had hap-
pened at the start of 2014.
Methods
Model and basecase scenario
We adapted a previously published,[5] stochastic individual-based simulation model of the
transmission dynamics ofM. tuberculosis (M.tb.) and fitted the model to current data on TB
and HIV epidemiology in South Africa (see S1 File for full details). Briefly, the model includes
TB and HIV natural history at an individual-level, with population level incidence sustained by
M.tb. transmission. Latent infection withM.tb. (which confers partial protection against pro-
gression to disease following re-infection) develops into active (sputum smear negative or posi-
tive pulmonary) TB disease at a rate that is higher shortly after (re-)infection and varies with
age. The model incorporated data on age-structured social mixing patterns, [6] as well as his-
toric and projected trends in demography [7]. Timing of development of TB disease after (re-)
infection is influenced by HIV status and CD4 count; HIV status and age influence the proba-
bility of TB disease being smear-positive. The model is built using C. All parameters are found
in Table A in S1 File.
In terms of the natural history of TB, individuals are born withoutM.tb infection; can ac-
quire anM.tb infection which may, or may not develop into active TB disease; and individuals
may, or may not have their active TB disease detected and initiate treatment. The force-of-in-
fection for TB is proportional to the prevalence of active TB, weighted by the infectiousness of
each prevalent TB case. We assume age-dependent mixing between different age groups, pa-
rameterized with data from a social contact study carried out in South Africa as part of ZAM-
STAR [6]. Upon infection withM.tb, individuals’ time-since-infection is tracked and they are
subject to a hazard of developing pulmonary TB disease per unit time. This hazard is higher in
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the first 2 years following (re-)infection, with an age-dependence following that used in [8]. In
subsequent years, the hazard of activation assumes a lower constant value. Individuals with an
M.tb infection have a partial protection against reinfection [9], however, a successful re-infec-
tion is treated identically to an initial infection.
Upon activation to pulmonary TB, 65% of cases in 20 year olds were assumed smear positive
among those without HIV infection, following the age pattern reported in [8], smear negative
TB assumed 23% as infectious as smear positive TB [10,11]. Active TB without treatment re-
sults in death (70% for smear-positive disease; 30% for smear-negative disease) or else self-cure
over a timescale of 3 years based on [12]. These alternatives are modelled as proportional haz-
ards with a Weibull-distributed time-to-event. Self-cure leaves individuals with anM.tb infec-
tion, and acts like a new infection in terms of activation risks.
Detection and initiation of treatment in those with active TB disease is assumed to occur
with a probability taken as the WHO estimate of the case-detection rate [13]. The timing of de-
tection and treatment initiation occurs at a certain fraction of an individual’s time-to-outcome
without detection and treatment (i.e. more rapidly progressing TB disease is detected propor-
tionately more rapidly).
For PLHIV, CD4+ T-cell counts of cells/mm3 (CD4) and TB risk were explicitly modelled,
as was ART initiation and its effect on CD4 count and life expectancy by age. A proportion of
PLHIV can be “linked to care” prior to qualifying for ART i.e. PLHIV who know their HIV sta-
tus but have a high CD4 count. This group start ART at the national guideline threshold. The
CD4 count at ART start for those detected as HIV positive with a CD4 count under the guide-
line threshold was taken from a distribution determined by data from a large set of ART co-
horts [14]. This distribution has a median CD4 value at ART start of 152 cells/mm3. HIV
incidence for each scenario was taken from a deterministic model of HIV transmission (see
S1 File) [15]. The model was calibrated to the situation in South Africa by varying seven key pa-
rameters (see S1 File).
The model basecase scenario assumes continued implementation of control methods as
used in South Africa up to mid-2013. This includes IPT to PLHIV at 10% coverage and ART to
those PLHIV with active TB at 15% coverage by 2014. Coverage was assumed to rise to 80%
coverage by 2015 to reflect the high adherence levels to ART guidelines [16]. In 2010, ART
guidelines were revised from initiating those with a CD4 count of less than 200 cells/mm3
(2004 guideline), to< 350 cells/mm3 with coverage to this group reaching 80% by 2012 [16].
The percentage of TB patients that were detected and started onto treatment was 69% [17].
This was independent of HIV status and was composed of both probability of detection and
pre-treatment loss to follow-up. Introduction and scale-up of the GeneXpert System (Cepheid,
Sunnyvale, CA) was implicitly included in the basecase scenario and we assumed this had no
impact on underlying parameters such as the rate at which patients start treatment as reported
in the most recent South African data [18,19]. Parameter values are given in the Table A in the
S1 File. The mean of 15,000 simulations was used for each outcome for each scenario. This
number of simulations was used so that stochastic error was then reduced below that of the
precision presented in the results and we could be confident in impact size to within 1%.
Interventions
Interventions were assumed to have started together on the 1st of January 2014 and to have had
short scale up times (1 year) to factor in time for preparations,[20] whilst leaving a maximum
amount of time to achieve impact before the beginning of 2016. The interventions under con-
sideration involve three separate control measures: ART, IPT, and improved TB case manage-
ment. These were grouped into four portfolios of interventions for investigation, which are
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outlined below and in Table 1 (full details in S1 File). The portfolios were chosen to represent
groups of existing interventions that are recommended in different guidelines (NSP and
WHO), or not yet in any (Novel Strategies). We then chose the most effective individual inter-
ventions and combined these into one portfolio that was predicted to give maximal impact
with current tools (Optimised).
Portfolios
1. NSP. This portfolio built on the basecase scenario but with higher adherence to the control
measures and additional interventions as discussed in the National Strategic Plan [4]. IPT
coverage was increased to 53% of newly detected PLHIV (as recorded in a recent HIV coun-
selling and testing campaign)[21] and set at 36 months in duration. The additional interven-
tions were: improved TB case management and periodic active case finding. The former
assumed increased treatment success (50% reduction in treatment failure) and a decreased
pre-treatment loss to follow-up (by 50%). The latter assumed annual screening rounds (not
just enhanced case finding [22]) reaching 30% of the population, as seen in recent HIV test-
ing campaigns,[23] and a high sensitivity test, such as GeneXpert. When taking into account
the acceptance rate of screening and pre-treatment loss to follow up, this intervention was
assumed to start 16% and 12% of previously undetected smear positive/negative TB on
treatment, respectively.
2. WHO. This portfolio was motivated by the World Health Organization guidelines on IPT
duration and ART [24]. The IPT coverage was assumed to be as in the NSP portfolio, but
the ART initiation guideline was increased in 2014 to a CD4 count of< 500 cells/mm3 with
coverage of those eligible reaching 90% by 2020.
3. Novel Strategies. This portfolio contained those interventions that are under consideration,
but are not yet included in any guidelines. We built on the NSP portfolio by assuming a)
ART was given universally (Universal Test and Treat, UTT): annually, 42% of PLHIV who
are not on ART were assumed to start ART via this intervention. No additional TB case de-
tection was included in this ART-only version of UTT; b) Continuous IPT was provided to
53% of PLHIV and c) 6 months of IPT was also provided randomly to the HIV negative
population with 20% coverage to investigate the potential new use of a currently existing
therapy, shown recently to be highly effective [25].
Table 1. Summary of the interventions included in each portfolio.
ART IPT Periodic
active case
ﬁnding
Improved
TB case
management*
Portfolio At CD4 < 350 At CD4 < 500 Universal
test and
treat
6 months
to PLHIV
36 months
to PLHIV
Continuous
to PLHIV
6 months to
HIV negatives
Coverage
Low High
Basecase X X
NSP X X X X
WHO X X
Novel
Strategies
X X X
Optimised X X X X X
* Decreased pre-treatment loss to follow-up and improved treatment success.
doi:10.1371/journal.pone.0122514.t001
Tuberculosis Prevention in South Africa
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4. Optimised. This portfolio combined the most effective interventions at the realistic cover-
age levels considered in the other portfolios, with an additional high coverage for periodic
case finding as this is advocated for in the National Strategic Plan [4]. It assumed the base-
case scenario plus a) UTT; b) 6 months IPT to 20% of HIV negatives; c) continuous IPT to
53% of PLHIV on starting ART; d) 50% decrease in pre-treatment loss to follow-up and an
increase in treatment success (a 50% decrease in treatment failure), and e) high coverage
(60%) periodic active case finding, with a high sensitivity test such as GeneXpert, starting,
annually, 32% and 24% of undetected sputum smear positive/negative TB on treatment.
Sensitivity analysis
We evaluated the robustness of our conclusions by exploring the “NSP” portfolio impact using
a sensitivity analysis of key model parameters. Full details are in the S1 File.
Results
Basecase
In line with recent data,[26] in the basecase scenario TB incidence and mortality were falling in
2012. The decrease past 2014 was due to declining HIV incidence via maintenance of high
ART coverage. Both incidence and mortality flattened from 2020 onwards (Fig 1).
Intervention Portfolios
Our results suggest, that the “Novel Strategies” and “WHO” portfolios could result in 32% and
22% reductions in TB incidence by 2016 (Fig 1 and Table 2). Both portfolios peak in impact be-
fore 2032 and neither achieved greater than 40% reductions in TB incidence or mortality at
any time point. The other two portfolios (“NSP” and “Optimised”) had a much larger impact
Fig 1. Basecase and impact of the four portfolios on TB incidence andmortality (/100,000/year). The “NSP” and “Optimised” portfolios have the biggest
impact. The dashed horizontal lines are the NSP 2016 targets. The solid vertical lines show the timings of the NSP deadlines for 2016 and 2032.
doi:10.1371/journal.pone.0122514.g001
Tuberculosis Prevention in South Africa
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by 2016 (Fig 1 and Table 2). By 2016, the “NSP” portfolio resulted in the prevention of a large
number of TB deaths (57%) but only a 32% reduction TB incidence.
The final, “Optimised”, portfolio nearly achieved the 2016 NSP goals with a 46% and 71%
reduction in incidence and mortality respectively (Fig 1 and Table 2). By 2050, both TB inci-
dence and mortality could be reduced by more than 75% using the “Optimised” portfolio.
However, TB incidence and mortality remained greater than the required zero new cases and
deaths NSP target for 2032.
When the portfolios were broken down into their contributing interventions, we found that
for the high impact portfolios (“NSP” and “Optimised”) most of the impact (on both incidence
and mortality) was attributed to reductions in pre-treatment loss to follow up and to periodic
(annual) active case finding. In the “NSP” portfolio ~40% of the impact was attributed to the
former and ~40% to the latter at low coverage (Fig 2, see S1 File for other portfolio
breakdowns).
Individual Interventions
The only single intervention that reduces both TB incidence and deaths by more than 50% by
2050 was annual active case finding in the general population (Fig 2 and S1 File). By 2032, the
high sensitivity, high coverage scenario reduced TB incidence by 48% and the number of TB
deaths by 58%. The intervention with the next highest impact was a 50% decrease in the pre-
treatment loss to follow up, with a ~30% and 52% reduction in TB incidence and deaths respec-
tively by 2032. Despite the interacting nature of the HIV and TB epidemics, the ART interven-
tions in general have only a modest impact, except for UTT, which had a long-term impact on
TB incidence of ~20%. The IPT interventions have little long-term impact on TB incidence or
deaths. Providing IPT to HIV negatives gave the biggest impact with a 13% and 20% decrease
in TB incidence and deaths respectively by 2050.
Reaching the targets
The model predicts that even if the “Optimised” portfolio had been immediately implemented
in 2014, the South African 2016 aims will not be achieved (Fig 1). The 2032 goals of zero new
cases and deaths are similarly unlikely to be achieved, with only two of the portfolios investigat-
ed here (“Optimised” and “NSP”) achieving greater than a 50% reduction in incidence and
mortality by 2032. Indeed, both these portfolios achieved this reduction before 2016, thus
Table 2. Percentage reduction in TB incidence andmortality in each portfolio compared to 2012 levels.
2016 2032 2050
NSP target 50% reduction Zero new cases and deaths No NSP target; WHO ‘elimination’ year [3]
Incidence Mortality Incidence Mortality Incidence Mortality
Portfolio Basecase 13 15 18 26 14 21
NSP 32 57 55 75 61 80
WHO 22 21 32 40 22 31
Novel Strategies 32 39 29 40 20 29
Optimised 46 71 70 86 76 89
Bold, underlined values indicate where the reductions are greater than the NSP targets for 2016 and 2032.
doi:10.1371/journal.pone.0122514.t002
Tuberculosis Prevention in South Africa
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partially fulfilling the NSP 2016 targets. Little difference was seen here in the impact of the
portfolios between 2032 and 2050.
Thus, our results suggest that high levels of TB control could be achieved using scale up of
current tools, as reductions of over 50% in the burden of TB could be achieved by 2032.
Sensitivity analysis
Varying key model parameters has little influence on the impact of the primary “NSP” portfo-
lio (S1 File). The parameters chosen were the probability that TB on ART is like that in those
without HIV, the protection from re-infection if latently infected, the probability of death if TB
is not cleared and the ratio of case detection rates by smear status in those without HIV. The
only parameter which generated a greater than 3% difference in the impact of the “NSP” port-
folio was the effect of ART on the risk of acquiring TB in PLHIV.
Under all parameter ranges explored, the overall difference in impact of the “NSP” portfolio
changed within the range of -6.5% to 1% (see S1 File for more details). This suggests that our
conclusion that the “NSP” portfolio would not achieve either of the NSP TB targets is robust.
Discussion
The results presented here suggest that large decreases in the tuberculosis burden of South Af-
rica could be achieved using existing technologies and simply increasing the numbers of pa-
tients starting TB treatment. Despite this, we find that even if these portfolios had been
immediately scaled up early in 2014, the 2016 and 2032 NSP targets are unlikely to be achieved.
Instead, these targets should be seen as useful for advocacy purposes, and goals to which signif-
icant progress can be made using current tools. Of the components explored, active case find-
ing and a reduction in pre-treatment loss to follow up were the most effective and could have a
Fig 2. The impact of the intervention components of the “NSP” portfolio on TB incidence (/100,000/
year). The dashed horizontal line is the NSP 2016 target. The solid vertical lines show the timing of the NSP
deadlines in 2016 and 2032.
doi:10.1371/journal.pone.0122514.g002
Tuberculosis Prevention in South Africa
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large impact. The individual interventions we considered fell into 3 categories with conclusions
that are broadly applicable to other settings: those involving IPT; those involving ART; active
case-finding and improved TB case management.
While there is good evidence that IPT is beneficial in reducing TB incidence in individuals
with HIV infections,[27] we find that policies involving IPT are likely to have limited popula-
tion-level impact on TB incidence. This stems from relatively pessimistic assumptions in light
of the most recent evidence around the durability of protection from IPT,[28–30] and from the
low prevalence of those on IPT in the population. We assumed only 10% of latent infections
withM. tb were cleared by a full course of IPT [28–30] and that a coverage of IPT of only 10%
or 53% of those PLHIV who were IPT naïve could be achieved per year. Although targeted at a
group of higher risk for TB (those on ART), scenarios with 6 or 36 months of IPT to those
starting ART never exceeded a population prevalence of more than 5% on IPT. On the other
hand, prescribing IPT to HIV-negative individuals, resulted in an ~15% prevalence in the gen-
eral population on IPT. This higher population coverage may have resulted in the greater im-
pact of this HIV-negative targeting, but the risks of such an approach due to side–effects [31]
would need to be carefully evaluated before it would be considered in practice.
We predict that widespread use of ART should have a noticeable population-level impact
on TB incidence as has been predicted previously [5]. In the short-term, this effect is driven by
the reduction in individual rates of TB among PLHIV; in the long term, averted HIV infections
also make a contribution, especially for UTT. This impact is despite the assumed lack of com-
plementary TB case finding as in standard UTT. Although ART reduces individual rates of TB,
those on ART still have 4-7-fold higher rates of TB than the HIV-negative population, and re-
ductions in mortality can result in increased HIV-prevalence. These competing effects are re-
sponsible for a plateau in impact in some ART scenarios, and mean that a policy emphasizing
ART initiation in those with TB, without bolstering general provision of ART, can increase
population TB incidence by keeping those at highest risk of TB alive [32].
While there is a lack of empirical evidence to support the impact of active case-finding in
the general population,[33] our modelling suggests that active case-finding and reductions in
pre-treatment loss to follow-up, which act by reducing the pool of infectious individuals, are
predicted to have a sustained and accumulating reduction on TB incidence. Our active case-
finding scenarios, while clearly very intensive, may not be unachievable. They are comparable
to levels achieved in previous active case finding interventions where 20% of undiagnosed cases
were thought to be diagnosed per 6 monthly campaigns [34]. We did, however, assume that
the population is uniformly reachable by case-finding rounds: that extra TB cases initiated on
treatment regardless of symptoms would not have higher rates of pre-treatment loss to follow-
up, or overload programme capacity, and that TB cases are uniformly infectious over time.
Relaxing any of these assumptions would reduce the predicted impact of active case finding.
Future work should specifically tackle the random screening assumption, with targeting of
high-risk sub-populations. Pairing a form of active case finding with UTT (as is standard for
UTT protocols) is likely to be a powerful tool for TB control.
Reductions in pre-treatment loss to follow-up are also predicted to be a potent interventions
and are more easily achievable within the current health infrastructure than active case finding,
by measures such as increased efficiencies in the diagnostic process, increased education and
improved follow-up by healthcare professionals [35]. These measures should enhance the im-
pact of the now widely available GeneXpert. Improvements in treatment initiation levels made
important contributions to reducing TB mortality, but resulted in smaller reductions in TB in-
cidence by affecting outcomes after transmission events had already occurred. This large im-
pact of improved case management has been seen in other models of South Africa TB control
[36].
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Our model does not explicitly include multi-drug resistance TB, however our key conclu-
sions are robust to this limitation. These key conclusions on overall NSP impact were also ro-
bust to our sensitivity analysis. However, because of computational resource constraints, this
sensitivity analysis was limited in scope. As such, although we believe it is unlikely, we cannot
exclude the possibility that there are combinations of baseline parameter values that would
lead the model to predict that the NSP scenario could reach the targets. We also designed our
interventions with rapid scale-up timings and thus did not tackle the important question of op-
erational feasibility. Our aim instead was to provide estimates of the upper limits of the impact
of current technologies. In relation to this, the relatively small difference between the impact of
the “Optimised” and “NSP” portfolios suggest that the additional cost of the higher coverage
included in “Optimised” would have to be carefully assessed against relative impact: the lower
coverage of active case finding and simply improving TB case management as included in the
“NSP” could alone be highly successful in the control of TB. As South Africa moves forward
with its adoption of the NSP, this work suggests that close attention should be paid to the im-
plementation and coverage of these interventions that were most successful in this model.
Conclusion
Although current control technologies are unlikely to achieve either of the South Africa targets
for TB control, this study predicts that interventions such as active case finding and a reduction
in pre-treatment loss to follow up could have a large impact. Our modelling provides evidence
on the likely differential relative impact of interventions, needed for future strategy implemen-
tation decisions and highlights two important methods that could have a significant impact on
future TB burden. We predict that even with the best deployment of the tools we currently
have available, new technologies will be needed to reach the 2032 South African TB targets for
control; however TB incidence could still be dramatically reduced using only existing control
measures.
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